Mark Robinson’s cases read like the inventory of a medical clinic: Baycol, fen-phen, Rezulin, Vioxx, Propulsid, Bextra, Celebrex and Zyprexa.
In almost every case, Robinson, founder of Robinson, Calcagnie & Robinson in Newport Beach, Calif., has served as lead or liaison counsel for plaintiffs lawyers in California. Robinson also has taken a major role in the national multidistrict litigation in several of those cases, including the federal cases against Merck & Co. Inc. over the painkiller drug Vioxx. Last year, he obtained a $51 million verdict against Merck in the first federal trial over Vioxx (three months ago, the judge lowered the award to $1.6 million). Barnett v. Merck & Co. Inc., No. 06-485, MDL 1657 (E.D. La.).
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
